A narrative review on sacubitril/valsartan and ventricular arrhythmias.

Content Provider	Europe PMC
Author	Wei, Zhaoyang Zhang, Meiwei Zhang, Qian Gong, Linan Wang, Xiangyu Wang, Zanzan Gao, Ming Zhang, Zhiguo
Copyright Year	2022
Abstract	Sacubitril/valsartan, the first angiotensin receptor neprilysin inhibitor approved by the Food and Drug Administration for marketing, has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in patients with chronic heart failure with a reduced ejection fraction. However, some researchers have also found that sacubitril/valsartan has an antiarrhythmic effect. The mechanism by which sacubitril/valsartan reduces the mortality associated with malignant ventricular arrhythmias is not precise. Many studies have concluded that ventricular arrhythmia is associated with a reduction in myocardial fibrosis. This article reviews the current understanding of the effects of sacubitril/valsartan on the reduction of ventricular arrhythmia and explains its possible mechanisms. The results of this study suggest that sacubitril/valsartan reduces the occurrence of appropriate implantable cardioverter-defibrillator shocks. Meanwhile, sacubitril/valsartan may reduce the occurrence of ventricular arrhythmias by affecting 3 pathways of B-type natriuretic peptide, Angiotensin II, and Bradykinin. The conclusion of this study is that sacubitril/valsartan reduces the number of implantable cardioverter-defibrillator shocks and ventricular arrhythmias in heart failure with reduced ejection fraction patients.
ISSN	00257974
Journal	Medicine
Volume Number	101
PubMed Central reference number	PMC9259167
Issue Number	27
PubMed reference number	35801732
e-ISSN	15365964
DOI	10.1097/md.0000000000029456
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2022-07-08
Publisher Place	Hagerstown, MD
Access Restriction	Open
Rights License	This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Subject Keyword	angiotensin receptor neprilysin inhibitor antiarrhythmic effect LCZ696 myocardial fibrosis sacubitril/valsartan ventricular arrhythmias
Content Type	Text
Resource Type	Article
Subject	Medicine